Laboratory Waste Sample Clauses

Laboratory Waste. All underground laboratory waste lines and risers at 4 locations throughout the building stubbed out at each floor level for future tenant connection. • Monitoring port installed at exterior of building. Life Safety System • Fire Alarm Control Panel in place with all required devices located within finished common areas. • Fire Sprinkler riser installed to each floor with distribution piping and sprinklers installed on each floor. Telecommunications • Three 4 inch conduits installed from exterior pull box to MPOE located ground floor. Eight 4 inch conduits installed below slab from central IDF on ground floor for future tenant use. • Telephone/data rooms constructed on each floor. Not Included in Warm Shell • DI water system. • Central Clean Dry Air (CDA) and vacuum equipment. • Distributed gases. 000 XXXXX XXXXXX ARCHITECTURAL DRAWINGS PREPARED BY XXX XXXXXXXX A-001 OVERALL SITE PLAN A-002 ENLARGED SERVICE YARD PLAN AND DETAILS A-003 SITE DETAILS A-004 ACCESSIBILITY REQUIREMENTS A-005 ENLARGED SITE PLAN A-101 1ST LEVEL FLOOR PLAN A-102 2ND LEVEL FLOOR PLAN A-103 3RD LEVEL FLOOR PLAN A-104 4TH LEVEL FLOOR PLAN A-105 ROOF LEVEL FLOOR PLAN A-106 PENTHOUSE ROOF PLAN A-101S 1ST LEVEL SLAB PLAN A-102S 2ND LEVEL SLAB PLAN A-103S 3RD LEVEL SLAB PLAN A-104S 4TH LEVEL SLAB PLAN A-105S ROOF LEVEL SLAB PLAN A-201 NORTH & EAST ELEVATIONS A-202 SOUTH & WEST ELEVATIONS A-301 LONGITUDINAL BUILDING SECTION A-302 CROSS BUILDING SECTION A-311 WALL SECTIONS A-312 WALL SECTIONS A-401 TOILET CORE ENLARGED PLANS & ELEVATIONS A-402 ENLARGED PLANS ELEVATORS & STAIRS A-403 ELEVATOR SECTIONS A-404 STAIR #1 SECTIONS A-405 STAIR #2 SECTIONS A-406 LOBBY ENLARGED PLAN A-407 LOBBY REFLECTED CEILING PLAN A-408 LOBBY REFLECTED CEILING PLAN - SECOND LEVEL A-411 LOBBY INTERIOR ELEVATIONS A-421 FINISH GENERAL NOTES AND SCHEDULE A-501 EXTERIOR DETAILS A-502 EXTERIOR DETAILS A-503 EXTERIOR DETAILS A-504 EXTERIOR DETAILS A-507 WALL SECTION DETAILS A-508 PENTHOUSE & ROOF SCREEN ELEVATIONS A-510 INTERIOR FRAMING DETAILS A-511 PENETRATION DETAILS A-512 EXTERIOR DETAILS - CANOPY DETAILS A-513 ROOF DETAILS A-514 ROOF DETAILS A-515 WATERPROOFING DETAILS A-520 RATED WALL DETAILS A-521 RATED WALL DETAILS A-523 INTERIOR DETAILS - ELEVATOR A-524 INTERIOR DETAILS- STAIR & RAILING A-525 INTERIOR DETAILS - CEILING A-526 INTERIOR DETAILS - LOBBY A-527 INTERIOR DETAILS - RECEPTION DESK A-52 MISCELLANEOUS DETAILS A-601 WALL TYPE SCHEDULE A-602 DOOR SCHEDULE A-604 WINDOW SCHEDULE 000 XXXXX XXXXXX MECHANICAL DRA...
Sample 1Sample 2
AutoNDA by SimpleDocs
Laboratory Waste. Labs are required to connect to the lab waste system, separate from the domestic waste system, to prevent contamination. A sampling manhole is provided on the lab waste line located in outside the building near gridlines 1/C.6, prior to the connection of the lab waste line to the sanitary sewer line directed to the municipal sewer system. Refer to the plumbing drawings for location. Lab waste and vent piping shall be fire-rated polypropylene (FRPP) with fusion joint fittings.
Sample 1
Laboratory Waste. Risers and drains as shown in the CAD files provided by Sublandlord to Subtenant. Electrical 4,000 amp, 480/277 volt Main Switch Board located on the G-l level below each building Normal power distribution rooms are located on each floor with 100 amp 480/277 volt lighting panels and 45KVA transformers along with 150 amp 120/208 volt convenience power panels. Emergency power distribution rooms are located on each floor with 100 amp 480/277 volt lighting panels and 45KVA transformers along with 150 amp 120/208 volt convenience power panels Life Safety Power are located on each floor with 50 amp 480/277 volt lighting panels and 50 amp 120/208 volt panels Motor Control Center for roof top equipment are located on the roof Power metering is provided on each floor to measure power consumption floor by floor. The Premises is provided with a 1,000 KW Generator with two, bypass isolation type, transfer switches. One for life safety functions while the other serves tenant loads. SMRH: 473310031.19 C-2 300 XXXXXX XXXXX BOULEVARD.SUBLEASE – PROTHENA BIOSCIENCES FINAL EXECUTION VERSION 0SDM-159614 SV\1619361.8 Life Safety System A new fire alarm system, with code compliant smoke control in each building, a control panel located on the ground floor within the new fire control room. Telecommunications
Sample 1
Laboratory Waste. 17 (h) Pest Control . . . . . . . . . . . . . . . . . . . . . . . . . . .18
Sample 1
Laboratory Waste. Tenant shall comply, at its sole cost and expense, with all orders, requirements and conditions now or hereafter imposed by any ordinances, laws, orders and/or regulations (hereinafter collectively called "regulations") of any governmental body having jurisdiction over the Demised Premises or the Building, whether required of Landlord or otherwise, regarding the collection, sorting, separation and recycling of waste products, garbage, chemicals, refuse and trash (hereinafter collectively called "waste products"), including, but not limited to, the separation of such waste products into receptacles reasonably approved by Landlord and the removal of such receptacles in accordance with any collection schedules prescribed by such regulations. Notwithstanding anything herein to the contrary, (i) Landlord shall have no obligation to accept from Tenant any waste products that are generated in connection with the use of the Demised Premises for laboratory purposes, and (ii) Tenant shall arrange for laboratory waste product collection, at Tenant's sole cost and expense, utilizing a contractor reasonably satisfactory to Landlord who is federally licensed, which waste product collection shall be in accordance with all applicable governmental laws, codes, rules, regulations, orders and statutes. Tenant shall pay all costs, expenses, fines, penalties and/or damages that may be imposed on Landlord or Tenant by reason of Tenant's failure to comply with any such regulations. Tenant shall maintain at the Demised Premises copies of all bills of lading, transportation manifests, disposal certificates and other evidence of disposal of such waste products in accordance with all applicable governmental laws, rules, codes, orders and regulations and shall provide Landlord with a copy of same upon Landlord's demand. Landlord shall permit Tenant to maintain an appropriate container for laboratory waste and other hazardous materials near the Loading Dock area, which container shall be stored in a locked and secure area. Tenant shall maintain such container in accordance with all applicable laws and regulations.
Sample 1
Laboratory Waste. ☐ Four separate risers near the center quadrant of each floor will be provided routed to one common drain that exits the building with to a sampling port outside the building. Electrical ☐ 4,000 amp, 480/277 volt Main Switch Board located on the G-1 level below each building ☐ Normal power distribution rooms will be located on each floor with 100 amp 480/277 volt lighting panels and 45KVA transformers along with 150 amp 120/208 volt convenience power panels. ☐ Emergency power distribution rooms will be located on each floor with 100 amp 480/277 volt lighting panels and 45KVA transformers along with 150 amp 120/208 volt convenience power panels ☐ Life Safety Power will be located on each floor with 50 amp 480/277 volt lighting panels and 50 amp 120/208 volt panels ☐ Motor Control Center for roof top equipment will be located on the roof SMRH:467812340.16 FINAL EXECUTION VERSION X-0 000 XXXXXX XXXXX XXXXXXXXX – NGM BIOPHARMACEUTICALS 0SDM-159614 ☐ Power metering will be provided on each floor to measure power consumption floor by floor. ☐ Each building will be provided with a 1,000 KW Generator with two, bypass isolation type, transfer switches. One for life safety functions while the other will serve tenant loads. Life Safety System ☐ A new fire alarm system, with code compliant smoke control in each building, a control panel located on the ground floor within the new fire control room.
Sample 1

Related to Laboratory Waste

  • Manufacturing Intrexon shall have the option and, in the event it so elects, shall use Diligent Efforts, to perform any manufacturing activities in connection with the Aquaculture Program that relate to the Intrexon Materials, including through the use of a suitable Third Party contract manufacturer. To the extent that Intrexon so elects, Intrexon may request that AquaBounty and Intrexon establish and execute a separate manufacturing and supply agreement, which agreement will establish and govern the production, quality assurance, and regulatory activities associated with manufacture of Intrexon Materials. Except as provided in Section 4.1, any manufacturing undertaken by Intrexon pursuant to the preceding sentence shall be performed in exchange for cash payments equal to Intrexon’s Fully Loaded Cost in connection with such manufacturing, on terms to be negotiated by the Parties in good faith. In the event that Intrexon does not manufacture Intrexon Materials or bulk quantities of other components of AquaBounty Products, then Intrexon shall provide to AquaBounty or a contract manufacturer selected by AquaBounty and approved by Intrexon (such approval not to be unreasonably withheld) all Information Controlled by Intrexon that is (a) related to the manufacturing of such Intrexon Materials or bulk qualities of other components of AquaBounty Products for use in the Field and (b) reasonably necessary to enable AquaBounty or such contract manufacturer (as appropriate) for the sole purpose of manufacturing such Intrexon Materials or bulk quantities of other components of AquaBounty Products. The costs and expenses incurred by Intrexon in carrying out such transfer shall be borne by Intrexon. Any manufacturing Information transferred hereunder to AquaBounty or its contract manufacturer shall not be further transferred to any Third Party, including any Product Sublicensee, or any AquaBounty Affiliate without the prior written consent of Intrexon; provided, however, that Intrexon shall not unreasonably withhold such consent if necessary to permit AquaBounty to switch manufacturers.

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials conducted by the Company, and to the knowledge of the Company, the preclinical tests and clinical trials conducted on behalf of or sponsored by the Company, that are described in, or the results of which are referred to in, the Registration Statement, the Time of Sale Prospectus or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures and all applicable laws and regulations, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58, and 312; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Time of Sale Prospectuses or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such Permits as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”) for the operation of the Company’s business as currently conducted, except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules and regulations of the Regulatory Agencies except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

  • Engineering Network engineering handles the technical aspects of the project, resolution of problems escalated by the NOC, planning for future network expansion, and improving performance and process. Engineering interacts directly with AOL and the NOC.

  • Stability During the Term, Seller shall conduct the commercial stability program pursuant to Regulatory Requirements applicable as of the Effective Date at its own expense. Should additional stability studies be required, the Parties shall agree, in good faith, upon the protocol, and associated charges, based on the then current charge rates for the staff services, with invoicing for such additional services to occur when the lot is placed on stability.

  • Testing Landlord shall have the right to conduct annual tests of the Premises to determine whether any contamination of the Premises or the Project has occurred as a result of Tenant’s use. Tenant shall be required to pay the cost of such annual test of the Premises; provided, however, that if Tenant conducts its own tests of the Premises using third party contractors and test procedures acceptable to Landlord which tests are certified to Landlord, Landlord shall accept such tests in lieu of the annual tests to be paid for by Tenant. In addition, at any time, and from time to time, prior to the expiration or earlier termination of the Term, Landlord shall have the right to conduct appropriate tests of the Premises and the Project to determine if contamination has occurred as a result of Tenant’s use of the Premises. In connection with such testing, upon the request of Landlord, Tenant shall deliver to Landlord or its consultant such non-proprietary information concerning the use of Hazardous Materials in or about the Premises by Tenant or any Tenant Party. If contamination has occurred for which Tenant is liable under this Section 30, Tenant shall pay all costs to conduct such tests. If no such contamination is found, Landlord shall pay the costs of such tests (which shall not constitute an Operating Expense). Landlord shall provide Tenant with a copy of all third party, non-confidential reports and tests of the Premises made by or on behalf of Landlord during the Term without representation or warranty and subject to a confidentiality agreement. Tenant shall, at its sole cost and expense, promptly and satisfactorily remediate any environmental conditions identified by such testing in accordance with all Environmental Requirements. Landlord’s receipt of or satisfaction with any environmental assessment in no way waives any rights which Landlord may have against Tenant.

  • Labeling Upon request, Lessee will xxxx the Equipment indicating Lessor's interest with labels provided by Lessor. Lessee will keep all Equipment free from any other marking or labeling which might be interpreted as a claim of ownership.

  • Samples Distributor shall provide to Subdistributor samples and prototypes that are not intended for resale to the extent such are made available by its Suppliers and at the same cost (if any) assessed by its Suppliers. Subdistributor shall promptly return all samples and prototypes to Distributor on the expiration or earlier termination of this Agreement as provided for in 0. Distributor retains all rights, title, and interest in and to all samples and prototypes before, during, and after the Term; and Loaned Instruments. Within a reasonable amount of time following the execution of this Agreement, Distributor will loan up to 2 sets of Instruments to the Subdistributor. Thereafter, Distributor may, at its discretion, loan additional sets of Instruments to Subdistributor from time to time pursuant to this provision. Any Instruments loaned to Subdistributor pursuant to this provision are referred to as “Loaned Instruments”. Subdistributor shall be permitted, in turn, to loan the Loaned Instruments to Customers that have purchased Products for use in connection with the Products; however, such Loaned Instruments will remain the property of Distributor and may be retrieved and retaken by Distributor at any time. Orders for Products and Instruments Purchase Orders. Subdistributor shall submit to Distributor written purchase orders for the Products and Instruments it elects to purchase and distribute pursuant to this Agreement, which orders shall include: (i) a list of the Products and Instruments ordered, (ii) the quantities of such Products and Instruments, and (iii) precise instructions for packaging, invoicing and shipping.

  • API A. Reliant shall supply to Cardinal Health for Manufacturing and Packaging, at Reliant’s sole cost, the API and applicable reference standards in quantities sufficient to meet Reliant’s requirements for each Product as further set forth in Article 4. Prior to delivery of any of the API or reference standard to Cardinal Health for Manufacturing and Packaging, Reliant shall provide to Cardinal Health a copy of the API Material Safety Data Sheet (“MSDS”), as amended, and any subsequent revisions thereto. Reliant shall supply the API, reference standards, and Certificate of Analysis FOB the Facility no later than thirty (30) days before the scheduled Manufacture Date upon which such API will be used by Cardinal Health. Upon receipt of the API, Cardinal Health shall conduct identification testing of the API. Cardinal Health shall use the API solely and exclusively for Manufacturing and Packaging under this Agreement. The maximum volume of API that Reliant supplies to Cardinal Health shall not exceed the amount reflected in the Firm Commitment and the next six (6) months of the Rolling Forecast.

  • Animals Except for guide, signal or service dogs in use by a blind, deaf or physically handicapped person or a watch dog used by the Tenant, no animals shall be allowed, even temporarily, anywhere in or on the Property without the Landlord’s prior written consent, which consent may be withheld, conditioned or delayed at the Landlord’s discretion.

Time is Money Join Law Insider Premium to draft better contracts faster.